Revance Therapeutics Inc
(NAS:RVNC)
$
3.04
-0.02 (-0.65%)
Market Cap: 317.35 Mil
Enterprise Value: 618.80 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 67/100 Revance Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 10, 2020 / 05:35PM GMT
Release Date Price:
$20.16
(+9.98%)
Operator
Mr. Prasad, you may begin.
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director
Thank you. Good afternoon, everyone. Thank you for dialing in. My name is Balaji Prasad. I lead spec pharma coverage for Barclays. This is a continuation of our virtual health care conference. And continuing with the day, we have with us today for the session with Revance, Mark Foley, CEO; and Jeanie from Investor Relations.
Also, owing to the nature of this format, there will be no Q&A session.
Mark and Jeanie, welcome, and thanks for taking your time.
Mark J. Foley
Revance Therapeutics, Inc. - President, CEO & Director
Thanks, Balaji. Thanks for having us.
Questions & Answers
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director
Yes, pleasure. Mark, it's been 5 months now since you took over as CEO. We had the pleasure of hosting you on your first roadshow a few months ago, and now it's great to have you here. Before I even
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot